CD274 and neoplasm: Immune checkpoint modulators, including program death-1 (PD-1) and program death-ligand 1(PD-L1) inhibitors targeting tumor-mediated immune tolerance, showed promising therapeutic outcomes by reversing cancer immunosuppression [6, 7].